research use only

MNS (3,4-Methylenedioxy-β-nitrostyrene) p97 inhibitor

Name: MNS (3,4-Methylenedioxy-β-nitrostyrene)
Brand: Selleck Chemicals
SKU: S4921
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S4921

MNS (3,4-Methylenedioxy-β-nitrostyrene) is a tyrosine kinase inhibitor that inhibits Syk, Src, and p97 with IC50 values of 2.5 μM, 29.3 μM, and 1.7 μM, respectively.

Chemical Structure

Molecular Weight: 193.16

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.77%

99.77

Related Targets	E3 Ligase DUB Proteasome E1 Activating SUMO E2 conjugating
Related Products	NMS-873 DBeQ CB-5339 NPD8733 ML240

Chemical Information, Storage & Stability

Molecular Weight	193.16	Formula	C₉H₇NO₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1485-00-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	MDBN			Smiles	C1OC2=C(O1)C=C(C=C2)C=C[N+](=O)[O-]

Solubility

In vitro
Batch:

DMSO : 39 mg/mL (201.9 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features	The nitro group of MNS (3,4-Methylenedioxy-β-nitrostyrene) is essential for its antiplatelet effect.
Targets/IC₅₀/Ki	p97 ^[2] 1.7 μM Syk ^[1] 2.5 μM Src ^[1] 29.3 μM
In vitro	MNS (3,4-methylenedioxy-β-nitrostyrene) completely inhibits 2 μM U46619-(a thromboxane A2 mimic), 5 μM ADP-, 100 μM arachidonic acid-(AA), 10 μg/ml collagen-, and 0.1 U/ml thrombin-induced platelet aggregation in a concentration-dependent manner with IC50 of 2.1 μM, 4.1 μM, 5.8 μM, 7.0 μM, and 12.7 μM, respectively. It inhibits platelet aggregation caused by either the calcium ionophore A23187 (1 μM) or the protein kinase C (PKC) activator PDBu (200 nM) with IC50 of 25.9 μM and 4.8 μM, respectively. This compound (20 μM) decreases thrombin-induced P-selectin expression on platelets to levels comparable to those observed in PGE1-treated platelets. It (20 μM) markedly inhibits thrombin-but not PDBu-induced MARCKS phosphorylation in platelets. MNS (20 μM) markedly inhibits protein tyrosine phosphorylation at either 0.5 min or 3 min after thrombin or collagen stimulation in platelets. ^[1] It stimulates UbG76V-GFP and ODD-Luc degradation with IC50 of 1.6 μM and 5.9 μM, respectively, and inhibits MG132-induced accumulation of the reporter with IC50 of 2.1 μM. ^[2] MNS inhibits Gram-positive (Staphylococcus aureus and Enterococcus faecalis) and Gram-negative (Escherichia coli and Pseudomonas aeruginosa) bacteria with minimum inhibitory concentrations (MICs) of 128 mg/L. ^[3] It is much more potent than genistein in inhibiting platelet aggregation and protein tyrosine phosphorylation, and is equally potent as inhibitors of platelet aggregation as 3,4-dimethoxy-β-nitrostyrene. This compound (20 μM) concentration-dependently prevents ATP release from platelets stimulated by thrombin or collagen, and inhibits thrombin-induced PAC-1 binding to human platelets. ^[4]
References	[1] https://pubmed.ncbi.nlm.nih.gov/16837624/ [2] https://pubmed.ncbi.nlm.nih.gov/21343295/ [3] https://pubmed.ncbi.nlm.nih.gov/16497504/ [4] https://pubmed.ncbi.nlm.nih.gov/17601492/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04473027	Terminated	Melanoma\|Cancer	University Hospital Ghent\|Jessa Hospital\|University Hospital Antwerp\|Algemeen Ziekenhuis Maria Middelares\|GZA Ziekenhuizen Campus Sint-Augustinus\|AZ Sint-Jan AV\|AZ Nikolaas\|AZ Sint-Lucas Gent\|AZ Sint-Lucas Brugge\|General Hospital Groeninge\|OLV van Lourdes Hospital Waregem\|AZ Damiaan\|AZ Delta\|ASZ Aalst\|Belgian Red Cross	September 1 2020	--
NCT01362244	Completed	Nasal Polyps	GlaxoSmithKline	May 12 2009	Phase 2
NCT00474799	Completed	Healthy	Javelin Pharmaceuticals	January 2007	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):